No Prescription |
 |
 | ||
|
TRXAMIC 500 Cyklokapron |
|
| ||
No Prescription » Prescription Drugs 16 » TRXAMIC 500 Cyklokapron This medication is used short-term in people with a certain type of bleeding disorder (hemophilia) to prevent and reduce bleeding from having a tooth pulled (extraction). It is also used in people with other high-risk bleeding conditions to control bleeding at such times as after surgery or an injury during heavy nosebleeds or during heavy menstrual bleeding.Tranexamic acid works by helping the blood clot normally to prevent and stop prolonged bleeding. It belongs to a class of drugs known as anti-fibrinolytics.How to use Tranexamic Acid OralTake this medication by mouth usually 2 to 4 times daily or as directed by your doctor.The dosage and length of treatment is based on your medical condition and response to treatment. Dosage is also based on your weight. Do not increase your dose take it more frequently or take it for a longer time than prescribed.Take this medication regularly to get the most benefit from it. To help you remember take it at the same times each day.Tell your doctor if your condition persists or worsens. Buy TRXAMIC 500 Cyklokapron and other Prescription Drugs 16 products online at Medstore. 622
About TRXAMIC 500 Cyklokapron: Product Type: Prescription Drugs 16 TRXAMIC 500 ( Cyklokapron Generic Tranexamic Acid ) TRXAMIC 500 (Cyklokapron Generic Tranexamic Acid) Cyklokapron Generic Tranexamic Acid 500mg Tabs 10 Cyklokapron Generic Tranexamic Acid TRXAMIC 500
View more Prescription Drugs 16 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
